American Journal of Hematology recently published the study result of BTK inhibitor orelabrutinib in patients with relapsed or refractory Marginal Zone Lymphoma, which investigated the efficacy and safety of orelabrutinib in r/r MZL.
American Journal of Hematology recently published the study result of BTK inhibitor orelabrutinib in patients with relapsed or refractory Marginal Zone Lymphoma, which investigated the efficacy and safety of orelabrutinib in r/r MZL.